In the article “OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer,” which began on page 1 of the April 10 issue of The ASCO Post, a few unfortunate errors appeared, notably an incorrect P value for the overall survival comparison (after its accurate first mention).
The correct paragraph should read:
“After a median follow-up of 3.5 years, there were 75 deaths in the olaparib arm and 109 deaths in the placebo arm, amounting to 3-year overall survival rates of 92.0% and 89.1%, respectively (HR = 0.68; 98.5% confidence interval [CI] = 0.47–0.97; P = .009). He reported the difference between the arms, after rounding, was 3.8% at 3 years and 3.4% at 4 years.”
The complete version of the article can be found online at www.ascopost.com. We regret the inaccuracies and apologize for any misleading information included in the article.
